Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting

SAN FRANCISCO, Aug. 4, 2017

"We are proud to support the recipients of the veterinary student sponsorship in their endeavor to broaden their knowledge of feline infectious disease and pediatrics, the focus of this year's conference.  It was a pleasure to work with the AAFP to interview and select the candidates.  We are excited about what the future holds for these focused students and eager to continue to build relationships with veterinary students across universities and disciplines," says KindredBio's Director of Veterinary Affairs, Valentine S. Williams, DVM, MS, DACVS.

"The Student Award Program, sponsored by KindredBio, is such a wonderful opportunity for students to become engaged as future leaders in feline veterinary medicine. We are excited that KindredBio and the AAFP were able to work together to support the education and networking opportunities of these talented emerging leaders," says AAFP President, Lauren E. Demos, BGS, BSc (Vet Biol), BVMS Hons (Vet Virology).

The AAFP recognizes the need for feline-focused practitioners and the education to support cats as a unique species, not as "small dogs." This includes initiatives such as the "cat friendly practice" designation and resources such as the educational website for cat caregivers, which can be accessed at www.catvets.com. The AAFP is dedicated to the advancement of feline practice by setting standards of feline care through publications, practice guidelines, position statements, and continuing education for the feline focused practitioner. KindredBio's collaboration with the AAFP engages the veterinary community by facilitating exchange of scientific data and ideas. The student sponsorship is just one part of this partnership.

About Kindred Biosciences 

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.